Crossmark

Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

Crossref DOI link: https://doi.org/10.1016/j.htct.2024.03.010

Published Print: 2024-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Vráblová, Lucia

Klamová, Hana

Skoumalová, Ivana

Navrátilová, Jana

Janská, Romana

Grohmann, Jan

Holzerová, Milena

Faber, Edgar https://orcid.org/0000-0002-3259-7791
Funding

Funding for this research was provided by:

Ministry of Health of the Czech Republic

Palacky University Olomouc
License Information

Text and Data Mining valid from 2024-12-01

Text and Data Mining valid from 2024-12-01

Version of Record valid from 2024-07-13
More Information

This article is maintained by: Elsevier

Article Title: Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

Journal Title: Hematology, Transfusion and Cell Therapy

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.htct.2024.03.010

Content Type: article

Copyright: © 2024 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below